Skip to main content
. 2021 Apr 13;13(8):1856. doi: 10.3390/cancers13081856

Figure 3.

Figure 3

Biochemical disease-free rate (bDFS), prostate cancer specific survival rate (PSS), and overall survival rate (OS) among conventional external beam radiotherapy (Conv EBRT), high dose external beam radiotherapy (HDEBRT), and high dose rate brachytherapy (HDR) boost groups; (a) biochemical control rates; (b) prostate cancer specific survival rate; and (c) overall survival rate.